|
Name |
cyclo(L-tyrosyl-L-phenylalanyl)
|
| Molecular Formula | C18H18N2O3 | |
| IUPAC Name* |
(3S,6S)-3-benzyl-6-[(4-hydroxyphenyl)methyl]piperazine-2,5-dione
|
|
| SMILES |
C1=CC=C(C=C1)C[C@H]2C(=O)N[C@H](C(=O)N2)CC3=CC=C(C=C3)O
|
|
| InChI |
InChI=1S/C18H18N2O3/c21-14-8-6-13(7-9-14)11-16-18(23)19-15(17(22)20-16)10-12-4-2-1-3-5-12/h1-9,15-16,21H,10-11H2,(H,19,23)(H,20,22)/t15-,16-/m0/s1
|
|
| InChIKey |
GRWVBLRIPRGGPD-HOTGVXAUSA-N
|
|
| Synonyms |
cyclo(L-Tyr-L-Phe); cyclo(L-tyrosyl-L-phenylalanyl); CHEBI:71611; CHEMBL191426; cyclo(L-phenylalanyl-L-tyrosyl); (3S,6S)-3-benzyl-6-(4-hydroxybenzyl)piperazine-2,5-dione; cyclo(Phe-Tyr); cyclo(TyrPhe); Cyclo[Phe-Tyr-]; cyclo(L-Phe-L-Tyr); (3S,6S)-3-benzyl-6-[(4-hydroxyphenyl)methyl]piperazine-2,5-dione; BDBM50505740; ZINC13376427; Q27139754; 1ED; cYF
|
|
| CAS | NA | |
| PubChem CID | 11438306 | |
| ChEMBL ID | CHEMBL191426 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 310.3 | ALogp: | 2.3 |
| HBD: | 3 | HBA: | 3 |
| Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 78.4 | Aromatic Rings: | 3 |
| Heavy Atoms: | 23 | QED Weighted: | 0.803 |
| Caco-2 Permeability: | -4.815 | MDCK Permeability: | 0.00002070 |
| Pgp-inhibitor: | 0.004 | Pgp-substrate: | 0.001 |
| Human Intestinal Absorption (HIA): | 0.871 | 20% Bioavailability (F20%): | 0.993 |
| 30% Bioavailability (F30%): | 0.659 |
| Blood-Brain-Barrier Penetration (BBB): | 0.041 | Plasma Protein Binding (PPB): | 87.78% |
| Volume Distribution (VD): | 0.496 | Fu: | 17.45% |
| CYP1A2-inhibitor: | 0.072 | CYP1A2-substrate: | 0.074 |
| CYP2C19-inhibitor: | 0.67 | CYP2C19-substrate: | 0.065 |
| CYP2C9-inhibitor: | 0.621 | CYP2C9-substrate: | 0.87 |
| CYP2D6-inhibitor: | 0.174 | CYP2D6-substrate: | 0.684 |
| CYP3A4-inhibitor: | 0.708 | CYP3A4-substrate: | 0.202 |
| Clearance (CL): | 7.276 | Half-life (T1/2): | 0.77 |
| hERG Blockers: | 0.141 | Human Hepatotoxicity (H-HT): | 0.376 |
| Drug-inuced Liver Injury (DILI): | 0.092 | AMES Toxicity: | 0.474 |
| Rat Oral Acute Toxicity: | 0.615 | Maximum Recommended Daily Dose: | 0.382 |
| Skin Sensitization: | 0.152 | Carcinogencity: | 0.267 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.011 |
| Respiratory Toxicity: | 0.031 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC001911 | ![]() |
0.720 | D0H6TP | ![]() |
0.447 | ||
| ENC003593 | ![]() |
0.718 | D06ZPS | ![]() |
0.411 | ||
| ENC004531 | ![]() |
0.616 | D0S2BV | ![]() |
0.403 | ||
| ENC001912 | ![]() |
0.616 | D0I0DL | ![]() |
0.378 | ||
| ENC004934 | ![]() |
0.616 | D0Y7EM | ![]() |
0.366 | ||
| ENC001909 | ![]() |
0.566 | D08FTG | ![]() |
0.337 | ||
| ENC003591 | ![]() |
0.554 | D0L0SW | ![]() |
0.336 | ||
| ENC005246 | ![]() |
0.532 | D09PZZ | ![]() |
0.327 | ||
| ENC002604 | ![]() |
0.532 | D0U7SH | ![]() |
0.322 | ||
| ENC004648 | ![]() |
0.512 | D0N4OW | ![]() |
0.319 | ||